Background Topical immune response modifiers are established for actinic keratosis (AK) treatment and efforts are underway to make further improvements to their efficacy and safety. Objectives To investigate the optimal dosing regimens of the Toll-like receptor 7/8 agonist resiquimod in terms of efficacy, safety and tolerability. Methods In a multicentre, partly placebo-controlled, double-blind clinical trial, we randomized 217 patients with AK lesions to 0Á03% resiquimod gel once-daily application three times per week for 4 weeks or seven times within 2 weeks or five times for 1 week (arms 1/2/3) followed by a treatment-free interval of 8 weeks and one repetition of the cycle. In two additional arms (arms 4/5), patients applied either resiquimod gel 0Á01% or 0Á03% three times per week up to a biological end point defined by skin erosion or for a maximum duration of 8 weeks. Clearance was assessed clinically and histologically. Results Complete clinical clearance ranged from 56% to 85% with the highest rate observed in arm 2. Resiquimod 0Á03% gel was more effective than 0Á01% gel. Clearance rates in arms 1/2/3 were comparable and higher than with placebo and were reached with 24, 14 and 10 gel applications, respectively. Overall, 128 patients (59%) experienced treatment-related adverse reactions. Conclusions Resiquimod 0Á03% gel is more effective than 0Á01% gel. From the perspectives of safety and tolerability, the lower concentration and shorter duration are preferable. The clinical response in arms 2/3 was reached with fewer gel applications. The dosing regimens that used the biological end point (arms 4/5) proved equally efficacious as predefined treatment durations and may therefore be suitable for personalized AK treatment.
Summary
Background Topical immune response modifiers are established for actinic keratosis (AK) treatment and efforts are underway to make further improvements to their efficacy and safety. Objectives To investigate the optimal dosing regimens of the Toll-like receptor 7/8 agonist resiquimod in terms of efficacy, safety and tolerability. Methods In a multicentre, partly placebo-controlled, double-blind clinical trial, we randomized 217 patients with AK lesions to 0Á03% resiquimod gel once-daily application three times per week for 4 weeks or seven times within 2 weeks or five times for 1 week (arms 1/2/3) followed by a treatment-free interval of 8 weeks and one repetition of the cycle. In two additional arms (arms 4/5), patients applied either resiquimod gel 0Á01% or 0Á03% three times per week up to a biological end point defined by skin erosion or for a maximum duration of 8 weeks. Clearance was assessed clinically and histologically. Results Complete clinical clearance ranged from 56% to 85% with the highest rate observed in arm 2. Resiquimod 0Á03% gel was more effective than 0Á01% gel. Clearance rates in arms 1/2/3 were comparable and higher than with placebo and were reached with 24, 14 and 10 gel applications, respectively. Overall, 128 patients (59%) experienced treatment-related adverse reactions. Conclusions Resiquimod 0Á03% gel is more effective than 0Á01% gel. From the perspectives of safety and tolerability, the lower concentration and shorter duration are preferable. The clinical response in arms 2/3 was reached with fewer gel applications. The dosing regimens that used the biological end point (arms 4/5) proved equally efficacious as predefined treatment durations and may therefore be suitable for personalized AK treatment.
What's already known about this topic?
• Actinic keratosis (AK) occurs in sun-exposed skin areas and may progress to squamous cell carcinoma if left untreated.
• AK treatments are often lengthy and demand high levels of commitment from patients.
What does this study add?
• Resiquimod gel at concentrations of 0Á03% and 0Á01% was effective for AK treatment on the balding scalp, forehead or face.
• A reduction in the total number of gel applications (from 24 to 10) gave comparable clearance rates and may therefore simplify AK treatments.
• Dosing regimens that used the biological end point of skin erosion proved to have equal levels of efficacy as the regimens that used a predefined treatment duration and may therefore be suitable for personalized AK treatment.
Actinic keratosis (AK) predominantly occurs on sun-exposed skin areas, appearing as irregularly shaped, scaly and erythematous macules.
1,2 The incidence rate of AK is increasing worldwide, 3 particularly in fair-skinned individuals living in sunny climates. 2 Men are more frequently affected than women 4 and prevalence increases with age, 5 with rates ranging from 11% to 26%. 2, 6 AK lesions are seen as part of a continuum along the path to the development of squamous cell carcinomas (SCCs). 7 The rate for AK transformation to SCC is highly variable ranging from 0Á1% to 10% or more. [8] [9] [10] [11] Therefore, most guidelines recommend that AK should be treated. 2 In recent years, topical therapies have become the preferred AK therapy. 1, 3, 12 Although the immune response modifier (IRM) imiquimod is an established treatment for AK, efforts are underway to increase efficacy, shorten treatment duration and reduce sideeffects in order to achieve an optimal AK treatment. Resiquimod is an IRM, which may potentially achieve greater efficacy than imiquimod based on its pharmacodynamic profile. 13 Resiquimod activates myeloid dendritic cells in addition to plasmacytoid cells and induces more interleukin-12 and tumour necrosis factor than imiquimod. 3, 14, 15 A previous phase II study investigated the safety and efficacy of topical resiquimod gel in the treatment of AK lesions.
14 Resiquimod gel in concentrations of 0Á01%, 0Á03%, 0Á06% or 0Á1% were applied three times per week for 4 weeks in one or two treatment cycles. The efficacy was high in all treatment groups, with overall complete clearance rates ranging from 77Á1% to 90Á3%. Drug-related influenza-like symptoms were observed primarily at the higher concentrations. Treatment with 0Á01% resiquimod gel demonstrated the best tolerability and provided the widest therapeutic window with an overall complete clearance rate of 77% and a severe erythema rate of 17%.
14 Against this background our primary objectives were to define the concentration and dosing schedule of resiquimod gel formulations at which complete clearance occurred, or at which a biological end point (clinical manifestation of skin erosion, i.e. the skin appears reddened, erosive and weeping) was achieved with subsequent complete clearance. A central element of this investigation was to reduce the total number of gel applications during the treatment cycle, compared with previous trials, 14, 16 and to evaluate the suitability of using a biological end point to terminate treatment rather than a predefined treatment duration. The secondary objectives were efficacy, local tolerability and safety of the various concentrations and dosing schedules of resiquimod gel.
Patients and methods

Trial design
In a prospective, randomized partly placebo-controlled, double-blind (arms 1/2/3), phase II, dose-finding study, we assessed the safety, tolerability and efficacy of topical resiquimod gel in patients with multiple AKs. In two additional arms (arms 4/5), patients applied resiquimod gel at a concentration of either 0Á01% or 0Á03% three times per week up to a biological end point. The study was approved by the ethics committees and regulatory authorities (Switzerland and Germany) and registered at ClinicalTrials.gov (NCT01583816).
Patients
Between May 2014 and November 2014, patients were screened and enrolled at 14 sites. Eligible patients were men and women > 18 years with at least two (one biopsied) clinically diagnosed AK lesions (indicator lesion ≥ 6 mm Ø) within a 25 cm 2 contiguous treatment area (balding scalp, forehead or face), who gave written informed consent. Patients with unstable significant medical conditions, active infections, immunosuppression or systemic cancer, autoimmune disorders, HIV, known thyroid abnormalities, depression, atopic dermatitis, rosacea, eczema, abuse, allergies or hypersensitivities to any product ingredients, or who were pregnant or lactating were excluded. AK-treatment-related therapy-free time intervals were defined for the time prior to the start of the trial. Aside from the trial medication no other systemic or topical therapies for AK were allowed.
Interventions
Patients topically self-administered the gel to predefined treatment areas, according to dosage and trial schedules ( Further efficacy end points were considered: CCC at the start of the second treatment cycle (arms 1/2/3), for instance, the disappearance of ≥ 75% of AK lesions [partial clinical clearance (PCC)] at trial end, histological proof of clearance of the indicator lesion at trial end, global efficacy judgement by investigator and patient by means of point scores (7-point scale, i.e. 1, significantly worse; 2, slightly worse; 3, no change; 4, slightly improved; 5, moderately improved; 6, significantly improved; 7, completely improved) at the starting point of the second treatment cycle (arms 1/2/3) and at trial end (arms 1/2/3/4/5). Quality of life (QoL) was assessed using the Skindex-29 questionnaire at visit 2 (baseline), after the first treatment cycle for arms 1/2/3, and after reaching the biological end point for arms 4/5, and at study end. 16, 17 The questionnaire encompasses the evaluation of three independent areas, i.e. symptoms, emotions and functioning. Safety was assessed based on treatment-emergent adverse events (TEAEs) and serious adverse events, local tolerability (burning, itching, pain) by means of symptom scoring (5-point scale, i.e. 0, absent; 1, slight; 2, moderate; 3, severe; 4, very severe), systemic tolerability, blood chemistry, global tolerability judgement by investigator and patient by means of point scores (1-6) at the starting point of the second treatment cycle (arms 1/2/3) and at trial end (arms 1/2/3/4/5) and by the number of withdrawals from the trial. Safety assessments were recorded at each patient visit.
Sample size, randomization, blinding and statistical analysis
Sample size was determined based on the objective of showing the superiority of resiquimod compared with placebo within a maximum of 24 weeks (v 2 -test) related to the primary outcome, i.e. CCC. For superiority testing using a twotailed a of 0Á05 (type 1 error) and b of 0Á20 (80% power), efficacy estimates of 25% for placebo (based on literature) and 70% for resiquimod (conservative calculation based on the earlier phase II study), 14 and a 2 : 1 allocation for resiquimod to placebo, the resulting sample size for comparing one active resiquimod arm to placebo was 32 patients receiving resiquimod and 16 patients receiving placebo. The total estimated sample size including all five active treatment arms plus the three matched placebos was 208.
Patients meeting eligibility criteria were randomized to one of five treatment arms (Table 1 ). In arms 1/2/3, patients were randomly assigned (2 : 1) to resiquimod gel or placebo. For treatment arms 4/5, parallel group randomization (1 : 1) was applied. Patients meeting eligibility criteria were assigned to consecutive numbers according to their enrolment and centre. Treatment arms 1/2/3 were controlled each by their corresponding matching placebo (multiplacebo group design) to preserve blinding. Treatment arms 4/5 were mutually blinded with no placebo control. Arms 4/5 were compared with the placebo group of arm 1. A trial-independent company prepared trial medication sets and delivered the sets at random once a patient was considered by a centre to be eligible. The trial medication set (serially numbered) with the lowest number was then delivered. Owing to the fact that the treatment lengths were different (Table 1) it may be possible to discern some treatment arms (e.g. arm 3). However, placebo and vera in addition to drug concentration were always blinded. Investigators, assessors, data analysts and patients remained blinded throughout the study. The identity of resiquimod/placebo treatments and resiquimod concentration was concealed using tubes that were identical in appearance for all products.
Results
Patients
Fourteen study centres participated in this trial. Most patients were enrolled in four study centres (two centres enrolled 39 patients, two centres enrolled 24 patients).
A total of 290 patients were screened, of whom 218 met eligibility criteria and were randomized. One patient was enrolled but discontinued early and never administered study medication. Thus, 217 white patients (33 women, 184 men), with an age range of 43-93 years (mean 70Á9-74Á1), who received at least one dose of trial medication were included in the intention-to-treat (ITT) and in the safety population (identical with ITT population) analyses (Table 2 ). At total of 37 patients were excluded because of major protocol violation(s). Therefore, 180 white patients (23 women, 157 men), with an age range of 47-90 years (mean 70Á1-74Á3) were included in the per-protocol (PP) population. Protocol deviations were related to study inclusion or exclusion criteria, safety and efficacy assessments, conduct of trial or patient management. The demographic characteristics of the patients at baseline were similar between study groups ( Table 2 ). All patients had AK proven by histology. Most patients were of skin phototype II (n = 134), 13 patients had phototype I, 67 patients had 
Outcomes
Primary outcome
In the ITT population, the overall CCC rate at study end was 67% (P = 0Á001 vs. placebo), 72% (P = 0Á004 vs. placebo), 70% (P < 0Á001 vs. placebo), 56% (P = 0Á009 vs. placebo) and 74% (P < 0Á001 vs. placebo) for treatment arms 1/2/3/4/5, respectively (Fig. 1) . The P-value in treatment arms 4/5 represents a v 2 -test for differences between the active treatment arm and the placebo of arm 1. In the PP population, the overall CCC rate at study end was 71% (P = 0Á001 vs. placebo), 85% (P < 0Á001 vs. placebo), 72% (P < 0Á001 vs. placebo), 56%
(P = 0Á014 vs. placebo) and 79% (P < 0Á001 vs. placebo) for treatment arms 1/2/3/4/5, respectively (Fig. 1) .
Secondary outcomes
In the ITT population, the CCC rate at the starting point of the second treatment cycle (arms 1/2/3) was 52% (P < 0Á001 vs. placebo), 55% (P = 0Á002 vs. placebo) and 52% (P = 0Á001 vs. placebo) for treatment arms 1/2/3, respectively (Fig. 2) .
In the PP population, 62% (P < 0Á001 vs. placebo), 63% (P < 0Á001 vs. placebo) and 55% (P = 0Á002 vs. placebo) of patients treated with resiquimod gel showed CCC after the first treatment cycle in treatment arms 1/2/3, respectively (Fig. 2) .
In the ITT population, PCC of AK lesions (≥ 75%) was observed in 87% (P < 0Á001 vs. placebo), 81% (P = 0Á004 vs. placebo), 77% (P < 0Á001 vs. placebo), 75% (P = 0Á002 vs. placebo) and 78% (P = 0Á001 vs. placebo) of patients of arms 1/2/3/4/5, respectively. In the PP population 90% (P < 0Á001 vs. placebo), 89% (P < 0Á001 vs. placebo), 79% (P < 0Á001 vs placebo), 74% (P = 0Á004 vs. placebo) and 83% (P < 0Á001 vs. placebo) of patients treated with resiquimod gel (arms 1/2/3/4/5) showed PCC at study end (Fig. 3) . Histological proof of clearance at study end in the ITT dataset has shown that significantly more patients randomized to the active drug were clear compared with placebo (of arm 1) in arm 1 (67% vs. 13%, P < 0Á001), arm 4 (66% vs. 13%, P < 0Á001) and arm 5 (76% vs. 13%, P < 0Á001). In treatment arms 2/3 the difference compared with placebo was not significant (arm 2, 58% vs. 25%, P = 0Á031; arm 3, 69% vs. 40%; P = 0Á067). In the PP population, 63% (arm 2) to 77% (arm 5) of patients who administered resiquimod gel showed histological proof of clearance of the indicator lesion. Results were significantly different from placebo (of arm 1) in arm 1 (65% vs. 13%, P = 0Á002), arm 4 (65% vs. 13%, P < 0Á001) and arm 5 (77% vs. 13%, P < 0Á001). Point scores of global judgements of efficacy by investigator were higher in all resiquimod treatment groups compared with placebo. At the starting point of the second treatment cycle (i.e. after the first treatment cycle and an 8-week treatment-free interval), the investigators judged the efficacy to be significantly better (ITT and PP populations) in the resiquimod treatment groups of arms 1/2/3 (ITT, P < 0Á001, P < 0Á001, P = 0Á007; PP, P < 0Á001, P < 0Á01, P = 0Á009). The mean point scores improved further at study end in these arms. Compared with placebo, the efficacy was rated as 'significantly improved' at study end in the active groups of treatment arms 1/2/3 for the ITT and PP populations (P < 0Á01). At study end, mean scores of active drug groups (arms 1/2/3/45) ranged from 4Á6 to 6Á4 in the ITT population [moderately (P < 0Á001) to significantly (P < 0Á001) improved] and from 6Á1 to 6Á3 [significantly improved (P < 0Á01)] in the PP population. In the placebo groups, the mean scores were 4Á5-4Á6 (slightly to moderately improved). At the starting point of the second treatment cycle, at least 65% of the AK lesions were judged to be significantly to completely improved (ITT and PP populations) by the investigators. At study end ≥ 80% and ≥ 79% of AK lesions were considered to be significantly or completely improved in both the ITT and PP population, respectively.
Also, the global judgement of efficacy by patient mean point scores was higher in the active drug groups than in the placebo groups at both the beginning of the second treatment cycle and at study end in all analysed populations. Analogously, the mean point scores of the active drug groups rose at the end of the study in treatment arms 1/2/3. Compared with placebo, efficacy was rated as significantly improved (P ≤ 0Á001) at study end in arms 1/2/4/5 of both the ITT and PP populations. The mean scores at study end ranged from 5Á9 to 6Á2 (significantly improved) and from 5Á9 to 6Á4 (significantly improved) in the ITT and PP populations, respectively. In the placebo groups, mean scores ranged from 4Á4 to 4Á9 (slightly to moderately improved) and from 4Á4 to 4Á8 (slightly to moderately improved) in the ITT and PP populations, respectively. At the starting point of the second treatment cycle, patients judged efficacy to be significantly improved in all active drug groups. The percentage of the patient global efficacy assessments that judged efficacy to be significantly to completely improved ranged from 59% to 78% after the first treatment cycle and from 73% to 85% at study end in the ITT population. In the PP population, percentages ranged from 59% to 81% and from 71% to 92% at both the beginning of the second treatment cycle and at study end, respectively.
The QoL assessment (Skindex-29) has shown that in the ITT and PP population, symptom scores improved in all resiquimod treatment groups from baseline to visit 8 or to study end, with the highest improvement compared with baseline seen in arm 3 [mean score reduction À3 (P < 0Á02) (ITT and PP)]. The same improvement was observed regarding emotion scores with the highest reduction (not statistically significant vs. placebo) in mean score values in arm 2 (ITT population À2Á3, PP population À2Á5) and arm 4 (ITT population À2Á0, PP population À2Á5). In the ITT and PP population, functioning scores improved in treatment arm 4 by À0Á6 (P = 0Á17) and À0Á7 (P = 0Á26) from baseline to study end, respectively.
Analysis of the treatment effect on the primary efficacy end point for possible confounders [sex, age < 65 years and ≥ 65 years, skin phototype and patient compliance (< 75%; ≥ 75%)], did not show statistically significant differences for any of these confounders or for each confounder by treatment interaction term for any of the five active treatments vs. placebo.
Safety
Patients in all treatment arms reported TEAEs (Table 3) . TEAEs for 128 patients (59%) were considered to be related to the trial drug [adverse drug reactions (ADRs)]. Within this class, 'application site erythema' and 'application scab' were the most frequently reported reactions with the highest incidences in treatment arm 5 (erythema 52%, scab 32%). Overall, 13 patients discontinued the trial owing to TEAEs -five owing to severe local skin reactions.
Discussion
The objectives of this trial were to define the concentration and dosing schedule of resiquimod gel at which CCC (no AK lesion according to clinical evaluation in the treatment area) occurred (arms 1/2/3), or at which a biological end point was achieved with subsequent CCC (arms 4/5). Efficacy was significantly higher in all resiquimod treatment groups compared with placebo, with overall CCC rates at the end of study ranging from 56% to 74% in the ITT population. The results for all resiquimod treatment arms were significantly better than placebo (P < 0Á01). Overall, the results were consistent with the hypothesis of 70% clearance with resiquimod vs. 25% with placebo and with results from a previous study that assessed resiquimod treatment in AK.
14 Results were confirmed in the PP population in which, the same overall CCC rate ranged from 56% to 85%. In the PP analysis, there were significant differences compared with placebo in treatment arms 1/2/3/5 (P < 0Á01).
With regard to CCC rates after the first treatment cycle (i.e. 4-week treatment plus an 8-week treatment-free period), significantly higher percentages compared with placebo were observed in all active treatment groups assessed and in both analysis populations.
Across all treatment groups, investigators and patients assessed resiquimod as having higher efficacy than that of placebo. The mean score values of global judgement of efficacy by the investigators at the study end for resiquimod were approximately 6 (significantly improved) and approximately 4Á5 (slightly to moderately improved) for the placebo. QoL (Skindex-29) symptom and emotion scores improved from baseline to study end in all resiquimod groups, supporting the subjective efficacy of the product.
With regard to safety, a higher percentage of patients treated with resiquimod (77%) reported adverse events such as general disorders and administration site conditions compared with placebo (62%). The highest indices of these events (mostly erythema and scab) were reported in treatment arm 5, which had the highest resiquimod dosing scheme and the highest overall complete clearance (ITT analysis). These events are seen in all therapies with IRMs and can be interpreted as typical signs for immunostimulatory therapies. The main reasons for discontinuation were general disorders and administration site conditions. Overall, the local tolerability of the trial medication was acceptable.
The safety profile is consistent with previously completed clinical phase II and III trials, which included 2100 patients (resiquimod in various indications). 13, 14, 16, 18, 19 In these trials ADRs were primarily local skin reactions such as erythema, scab, oedema, erosion, ulceration and vesicles. Systemic ADRs included infections (application site pustules, nasopharyngitis and application site infection) and nervous system disorders (headache, paraesthesia). In the study conducted by Szeimies et al., influenza-like symptoms were reported in one patient (3%) treated with resiquimod 0Á03% gel.
14 In this study, three influenza-like side-effects occurred in treatment arm 1 and arm 3. The symptoms are possibly related to cytokine release/induction, an activity associated with the proposed mechanism of action of resiquimod as an IRM.
One may compare our data with previous investigations related to topical AK treatment. In pooled analysis of trials using similar end points and clinical definitions for CCC and PCC, the rates of clearance were higher for ingenol mebutate (total of three applications for AKs on face or scalp, evaluated at day 57 after trial initiation) than with placebo (42Á2% vs. 3Á7% and 63Á9% vs. 7Á4%, respectively). 20 For imiquimod 3Á75% (up to 42 applications, evaluated at day 119 after trial initiation), the rates of clearance were also higher than with placebo (34Á0% vs. 5Á5% and 53Á7% vs. 12Á8%, respectively). 21 For 5-fluorouracil 0Á5% and salicylic acid 10% (up to 84 applications, evaluated at day 140 after trial initiation), the rate of CCC was higher than with placebo (55Á4% vs. 15Á1%). 22 In a recent trial, a compounded mixture of 0Á005% calcipotriol ointment (Taro Pharmaceuticals, Hawthorne, NY, U.S.A.) with 5% 5-fluorouracil cream (Taro Pharmaceuticals) or Vaseline with 5% 5-fluorouracil cream at a 1 : 1 weight ratio (eight applications, evaluated at day 56 after trial initiation), the rates of CCC and PCC of AKs on the face were 27Á0% vs. 0% and 80% vs. 0%, respectively.
23
For resiquimod arms 1/2/3 (24, 14, 10 applications, evaluated at day 168, 140, 126 after trial initiation, respectively), the rates of CCC and PCC were also higher than with placebo (71-85% vs. 13-21% and 79-90% vs. 27-36%, respectively) and for resiquimod arms 4/5 (up to 24 applications, evaluated at day 112 after trial initiation), the rates of these clearances were 56-79% vs. 19% and 74-83% vs. 31%, respectively.
Some limitations apply to this investigation. In order to study the influence of (i) drug concentration, (ii) dosing schedule, (iii) the usefulness of a biological end point as a marker for treatment cessation and (iv) to relate to a previous phase II study with the same resiquimod formulation (arm 1), the number of patients per arm was small (n = 31-38). There was no assignation of a direct placebo arm to the treatment arms 4/5. The investigation was focused only on AK treatment of the balding scalp, forehead and face. The clinical clearance at study end proved the superiority of verum vs. placebo. However, the histological proof of clearance in treatment arms 2/3 vs. placebo was not significant. On the one hand, this may be explained by the fact that the treatment duration of arm 2/3 was shorter than in arm 1 [24 applications vs. 14 applications vs. 10 applications (2 cycles)]; on the other hand, it emphasizes the importance of the parallel use of clinical and histological methods. However, this statement is based on only one indicator lesion.
Overall, resiquimod 0Á03% is numerically more effective than the lower concentration of 0Á01%. Effectiveness in the placebo-controlled arms 1/2/3 was largely comparable between the treatment arms with regard to CCC rates achieved with resiquimod compared with corresponding placebo. However, the clinical response in arms 2/3 was reached with significantly fewer gel applications, i.e. 14 and 10 applications, respectively (rather than 24). In treatment arm 5 (which used the same resiquimod strength as in treatment arm 1/2/3, treatment cessation elicited by biological end point) the average number of gel applications was 22Á2 (median 13).
Given the comparable effectiveness of therapeutic regimens with the 0Á03% resiquimod gel formulations, the two lowest dose/regimens/durations evaluated in this study [one treatment cycle; arm 2 (0Á03%), seven times within 2 weeks and arm 3 (0Á03%), five times for 1 week] offer an effective topical IRM therapy with a considerably shorter treatment period compared with current IRM therapies. The dosing regimens using the biological end point of erosion proved equally efficacious as the fixed-time regimens promising a novel personalized approach in treating AK.
